A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy

Part of paid clinical trials in Arvada, Colorado.

Sponsor
Vertex Pharmaceuticals Incorporated
Study ID
NCT07807995
Phase
PHASE3
Status
Enrolling By Invitation

Conditions

  • Immunoglobulin A Nephropathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Povetacicept — DRUG
    Subcutaneous injection administration.

Study Details

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).

Key Dates

First listed
Sep 8, 2026
Start date
Sep 17, 2026
Status verified
Oct 2026
Primary completion
Dec 28, 2029
Completion
Dec 28, 2029

Study Design

Enrollment
605 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Povetacicept
    Participants will receive Povetacicept every 4 weeks (Q4W) for 104 weeks.

Primary Outcome Measure

Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: From Day 1 up to Week 112 ]

Locations (3)

FacilityCityStateZIPSite coordinators
Western Nephrology - ArvadaArvadaColorado80002-
CTR Oakwater, LLCOrlandoFlorida32806-
Prolato Clinical Research Center - Kirby DrHoustonTexas77054-

Find similar trials in Arvada, CO

By research site
Western Nephrology - Arvada· Arvada, COCTR Oakwater, LLC· Orlando, FLProlato Clinical Research Center - Kirby Dr· Houston, TX

Related Studies